• Janice M. Emerling CNM, MSN,

    Corresponding authorSearch for more papers by this author
    • Janice M. Emerling, CNM, MSN, is a British-trained nurse-midwife, who completed the precertificarion course at University of Arizona and an M.S.N. at the University of Maryland. She is a staff midwife at the Center for Addiction and Pregnancy (CAP), Francis Scott Key Medical Center (FSKMC) in Baltimore, Maryland.

  • Patricia Paluzzi CNM, MPH,

    Search for more papers by this author
    • Patricia Paluzzi, CNM, MPH, is a graduate of the Los Angeles County/University of Southern California midwifery program and the Johns Hopkins University (JHU) School of Public Health and Hygiene. She is lead nurse-midwife at CAP at FSKMC, Baltimore, Maryland.

  • JoAnne Leiva CNM,

    Search for more papers by this author
    • JoAnne Leiva, CNM, is a graduate of the midwifery program of the State University of New York Health Science Center at Brooklyn. She is a staff nurse-midwife at CAP at FSKMC, Baltimore. Maryland.

  • Vanessa E. Cullins MD, MPH

    Search for more papers by this author
    • Vanessa E. Cullins, MD, MPH, was graduated from JHU School of Medicine, did her OB-GYN residency at Johns Hopkins Hospital, received her M.P.H. at JHU School of Public Health and Hygiene, and is an instructor in the Department of OB-GYN at FSKMC, Baltimore, Maryland.

Janice Emerling, CNM, MSN, PO Box 5872, 1103 Stafford Road, Darlington, MD 21034.


Subdermal contraceptive implants have only recently been approved for use in the United States. At present, only one subdermal contraceptive implant, Norplant, is approved in the United States. This article describes the development of Norplant, its efficacy and safety, a description of the system, education for clients, side effects, indications and contraindications, insertion and removal, incorporation into midwifery practice, and education for health professionals regarding its use.